About Nuago Therapeutics
Nuago Therapeutics is a company based in Chicago (United States) founded in 2020 by Robert Schickel.. Nuago Therapeutics has raised $150 thousand across 2 funding rounds from investors including HHS. Nuago Therapeutics operates in a competitive market with competitors including Stoke Therapeutics, Vico, MiNA Therapeutics, ReNAgade and CureVac, among others.
- Headquarter Chicago, United States
- Founders Robert Schickel
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$150 K (USD)
in 2 rounds
-
Latest Funding Round
$400 K (USD), Grant
Sep 19, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nuago Therapeutics
Nuago Therapeutics has successfully raised a total of $150K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $400 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $400,000
-
First Round
First Round
(25 Oct 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Grant - Nuago Therapeutics | Valuation |
investors |
|
| Oct, 2022 | Amount | Seed - Nuago Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuago Therapeutics
Nuago Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuago Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nuago Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuago Therapeutics Comparisons
Competitors of Nuago Therapeutics
Nuago Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stoke Therapeutics, Vico, MiNA Therapeutics, ReNAgade and CureVac, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing
|
|
| domain | founded_year | HQ Location |
RNA modulating therapies for genetic neurological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small activating RNA therapeutics are developed to restore gene function.
|
|
| domain | founded_year | HQ Location |
RNA-based medicines are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics against cancer and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of RNA synthesis platform for gene therapeutics
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Nuago Therapeutics
When was Nuago Therapeutics founded?
Nuago Therapeutics was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Where is Nuago Therapeutics located?
Nuago Therapeutics is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Who is the current CEO of Nuago Therapeutics?
Robert Schickel is the current CEO of Nuago Therapeutics. They have also founded this company.
Is Nuago Therapeutics a funded company?
Nuago Therapeutics is a funded company, having raised a total of $150K across 2 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Oct 25, 2022.
What does Nuago Therapeutics do?
Nuago Therapeutics was founded in 2020 in Chicago, United States, within the biotechnology sector. Gene therapies targeting treatment-resistant cancers are developed, including single construct short RNAs and lipo-polyplex nanoparticles. These are applied to ovarian cancer (NU001) and prostate cancer (NU002), where tumor cells are targeted and killed. Potential enhancements in platinum sensitivity are also explored through this approach.
Who are the top competitors of Nuago Therapeutics?
Nuago Therapeutics's top competitors include MiNA Therapeutics, Vico and Stoke Therapeutics.
Who are Nuago Therapeutics's investors?
Nuago Therapeutics has 1 investor. Key investors include HHS.